Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)

Summary

The main objectives of the study are to demonstrate pharmacokinetics (PK) similarity between ABP 692 and Ocrelizumab (US), and ABP 692 and Ocrelizumab (EU), and to demonstrate pharmacodynamics (PD) similarity between ABP 692 and Ocrelizumab reference product (RP) based on assessment of the suppression of new active brain lesions over 24 weeks as assessed by magnetic brain imaging (MRI).

Timeline

Start

2025-01-13

Primary completion

2027-01-15

Completion

2027-12-17

Drugs

Indications